Pharma BD Deal Intelligence
A $1.2B bet that wrote itself off within a year — goodwill fully impaired in FY2018, the rare-disease pipeline asset failed Phase 3, and the buyer went bankrupt twice.
Full analysis, sources & comparables →Mallinckrodt's $1.2B Sucampo bet is less about Amitiza's mature CIC franchise and more about two Phase 3 rare-disease shots-on-goal—VTS-270 in NPC and…
The acquisition brings near-term net sales and earnings accretion through Amitiza and bolsters our pipeline in rare diseases with VTS-270 and…
VTS-270 missed its Phase 2b/3 primary endpoint in Niemann-Pick Type C, with neither arm progressing as expected—a confusing readout that called the program's…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mallinckrodt agreed to acquire Sucampo Pharmaceuticals via tender offer at $18.00/share in cash, total transaction value approximately $1.2B. The deal added Sucampo's lead commercial product Amitiza (chronic constipation) plus two Phase 3 rare disease assets: CPP-1X/sulindac for familial adenomatous polyposis and VTS-270 for Niemann-Pick Type C. Closed Q1 2018.
A $1.2B bet that wrote itself off within a year — goodwill fully impaired in FY2018, the rare-disease pipeline asset failed Phase 3, and the buyer went bankrupt twice.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. (this deal) | 2017 | $1.2B | 19 |
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Therakos, Inc. | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Ikaria, Inc. | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. | 2014 | $5.6B | 18 |
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation | 2017 | $425M | 12 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
← Browse all deals · How we score deals
More: 2017 deals · Mallinckrodt plc deals · Gastroenterology deals